Subject: clinical trial | Original Article | disability scales | finger and foot tapping | Multiple sclerosis | progressive MS | outcome measurement
Background While magnetic resonance imaging contrast-enhancing lesions represent an excellent screening tool for disease-modifying treatments in relapsing–remitting multiple sclerosis (RRMS), this biomarker is insensitive for testing therapies against compartmentalized ... View more
11 Kosa P, Ghazali D, Tanigawa M, et al. Development of a sensitive outcome for economical drug screening for progressive multiple sclerosis treatment. Front Neurol 2016; 7: 131.
6 Floeter MK Mills R Progression in primary lateral sclerosis: a prospective analysis. Amyotroph Lateral Scler: official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 2009; 10: 339–346.
7 Komori M Lin YC Cortese I Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Translat Neurol 2016; 3: 166–179.